Moolec Science SA(US:MLEC)2024-10-02 16:37Financial Data and Key Metrics Changes - Normalized revenues and other income increased by $4.8 million year-over-year, from approximately $1 million in 2023 to $5.8 million in 2024, attributed to the consolidation of the soy product ingredient business [12] - Normalized cost of sales rose from close to $1 million in 2023 to $4.5 million in 2024, aligning with revenue growth [12] - SG&A and R&D expenses increased by $3.1 million, from $6.2 million in 2023 to $9.3 million in 2024, primarily due to non-cash items and the consolidation of the soy ingredient business [12] - Cash used in operating activities increased by $1.8 million, from $7.5 million in 2023 to $9.3 million in 2024 [13] - Cash position stood at approximately $5.4 million as of Q4 2024, bolstered by the purchase of 15,000 tons of HB4 soybean [13] Business Line Data and Key Metrics Changes - The commercialization of Piggy Sooy products is on the horizon, with USDA approval received, allowing for transport and distribution with individual permits [9][10] - Glaso products are being prepared for commercialization, with trial production and farmland secured for production [5][10] - Field trials for Piggy Sooy have commenced in Ohio, Missouri, and Iowa to increase seed production and collect environmental data [10] Market Data and Key Metrics Changes - The company has established traction in the U.S. market, with a major global CPG company signing an offtake agreement for Glaso [22][28] - The expected revenue from the soy protein ingredient business for fiscal year 2025 is projected to be around $6 million, with Glaso anticipated to contribute approximately 15% of total revenue [28] Company Strategy and Development Direction - The company aims to enhance operational expertise in launching new products, focusing on Glaso as a strategic commercialized product [16][17] - Plans include scaling up seed inventory and fine-tuning operations to ensure high-quality products while managing costs [17] - The company is committed to making progress on regulatory pathways and expanding its innovation pipeline with new proteins and molecular product development [18] Management's Comments on Operating Environment and Future Outlook - Management believes fiscal year 2025 will be pivotal, with expectations for commercialization of new science-based ingredients to begin taking off [15] - The company is optimistic about the growth potential of Glaso and its contribution to overall revenue in the coming years [28][58] - Management is focused on building relationships with potential customers and ensuring the marketability of products in the pipeline [18] Other Important Information - The company has established a new operational hub in the U.S. to enhance team collaboration and efficiency [19] - The R&D collaboration with Bunge aims to improve safflower varieties for specific applications, with a focus on both biofuel and bioreactor platforms [51] Q&A Session Summary Question: Details on the offtake agreement for Glaso - The agreement is with a major global CPG company, a three-year contract with potential for expansion, focusing on pet food applications [22][23][28] Question: Commercialization and expansion plans - Glaso applications include dietary supplements, nutritional beverages, and pet food, with expectations for significant market interest [33][34] Question: Additional commercial uptake agreements for Glaso - No additional agreements signed yet, but the company is optimistic about future agreements and plans to market the product at industry shows [47] Question: Steps to drive awareness and adoption of PMF products - The company focuses on B2B communications, targeting R&D departments of potential customers and maintaining transparency about its technology [62][65] Question: Revenue growth expectations for safflower oil products - Glaso is expected to contribute around 15% to total revenue in fiscal year 2025, with growth anticipated in subsequent years [58]